Self-collection for under-screened women in a national cervical screening program: Pilot study

Current Oncology

Volumn 25, Issue 1, 2018, Pages e27-e32

  Saville, M ^a,b   Hawkes, David ^a,b   Mclachlan, E ^c   Anderson, S ^d   Arabena, K ^c  

^a VICTORIAN CYTOLOGY SERVICE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Baarlinjan Medical Clinic   (Australia)

Author keywords

Cervical cancer screening; Diagnostic testing; Human papillomavirus (HPV); Self collection

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY; CANCER SCREENING; COLPOSCOPY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; PILOT STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; YOUNG ADULT;

EID: 85042768087     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.25.3915     Document Type: Article

References (19)

1. NPS. NPS MedicineWise. Special ed. NPS Radar; 2015.
2. Whop LJ, Cunningham J, Condon JR. How well is the National Cervical Screening Program performing for Indigenous Australian women? Why we don’t really know, and what we can and should do about it. Eur J Cancer Care 2014;23:716–20.
3. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
4. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072–9.
5. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med 2017;14:e1002388.
6. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172–83.
7. Register VCS. Statistical Report 2014. Melbourne, Australia; 2014.
8. (AIHW) AIoHaW. Cervical Screening in Australia 2012–2013. Cancer Series Canberra: AIHW; 2015.
9. Barbaro B, Brotherton JM, Gertig DM. Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria. Med J Aust 2012;196:445.
10. Sultana F, English DR, Simpson JA, et al. Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia. Int J Cancer 2016;139:281–90.
11. Osborne SL, Tabrizi SN, Brotherton JM, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 2015;33:201–8.
12. Brotherton JM, Condon JR, McIntyre PB, et al. Human papillomavirus prevalence to age 60 years among Australian women prevaccination. Sex Health 2015;12:353–9.
13. Sultana F, Gertig DM, Wrede CD, et al. A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. J Clin Virol 2015;69:210–3.
14. Lam JUH, Rebolj M, Ejegod DM, Pedersen H, Rygaard C, Lynge E, et al. Prevalence of human papillomavirus in self-taken samples from screening nonattenders. J Clin Microbiol 2017;55(10):2913–23.
15. McLachlan E, Anderson S, Hawkes D, Saville M, Arabena K. Completing the cervical screening pathway: Factors that facilitate the increase of self-collection uptake among underscreened and never-screened women, an Australian pilot study. Curr Oncol 25:e17-26.
16. Vassilakos P, Catarino R, Bougel S, et al. Use of swabs for dry collection of self-samples to detect human papillomavirus among Malagasy women. Infect Agent Cancer 2016;11:13.
17. Hawkes D, Tan G, Caruana M, Knight B, Canfell K, Saville M. An analysis of invalid Human Papillomavirus DNA results as part of the Compass Trial on Cervical Screening. 31st International Papillomavirus Conference. Cape Town, South Africa; 2017.
18. Cuschieri K, Geraets D, Cuzick J, et al. Performance of a cartridge-based assay for detection of clinically significant human papillomavirus (HPV) infection: lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol 2016;54:2337–42.
19. NPAAC. Requirements for Laboratories Reporting Tests for the National Cervical Screening Program. 1st ed. Canberra: Australian Government Department of Health; 2017.